Patients Treated With Natural Killer Cells [clinicaltrials_resource:NCT00625729/group/P1]
Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.
participant counts in P1 for milestone 2 of NCT00625729 [clinicaltrials_resource:NCT00625729/milestone/1/p/1]participant counts in P1 for milestone 3 of NCT00625729 [clinicaltrials_resource:NCT00625729/milestone/2/p/1]participant counts in P1 for milestone 4 of NCT00625729 [clinicaltrials_resource:NCT00625729/milestone/3/p/1]participant flow for clinicaltrials:NCT00625729 [clinicaltrials_resource:d203acba98c95d4c34c0d1ab9dd04b4d]
group [clinicaltrials_vocabulary:group]
Patients Treated With Natural Killer Cells [clinicaltrials_resource:NCT00625729/group/P1]
Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.
Bio2RDF identifier
NCT00625729/group/P1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00625729/group/P1
group id [clinicaltrials_vocabulary:group-id]
description
Patients with relapsed non-Hod ...... and 1 dose cyclosphosphamide.
@en
identifier
clinicaltrials_resource:NCT00625729/group/P1
title
Patients Treated With Natural Killer Cells
@en
type
label
Patients Treated With Natural Killer Cells [clinicaltrials_resource:NCT00625729/group/P1]
@en